e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Jules L. Derks, Robert Jan van Suylen, Erik Thunnissen, Michael A. den Bakker, Harry J. Groen, Egbert F. Smit, Ronald A. Damhuis, Esther C. van den Broek, Ernst-Jan M. Speel, Anne-Marie C. Dingemans
Source:
Eur Respir J, 49 (6) 1601838; 10.1183/13993003.01838-2016
Journal Issue:
June
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jules L. Derks, Robert Jan van Suylen, Erik Thunnissen, Michael A. den Bakker, Harry J. Groen, Egbert F. Smit, Ronald A. Damhuis, Esther C. van den Broek, Ernst-Jan M. Speel, Anne-Marie C. Dingemans. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?. Eur Respir J, 49 (6) 1601838; 10.1183/13993003.01838-2016
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Large cell neuroendocrine carcinoma of the lung: chemotherapy regimen depends on how “large” your diagnostic criteria are
Source: Eur Respir J, 50 (4) 1701292; 10.1183/13993003.01292-2017
Year: 2017
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010
Management of extensive disease-small cell lung cancer
Source: Eur Respir Mon; 2009: 44: 310–317
Year: 2009
Large cell neuroendocrine carcinoma of the lung: Experience with 20 resected cases
Source: Eur Respir J 2003; 22: Suppl. 45, 250s
Year: 2003
Radiotherapy vs. radio-chemotherapy of the inoperable non small cell lung cancer - a phase-III-study
Source: Eur Respir J 2001; 18: Suppl. 33, 318s
Year: 2001
Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas
Source: Eur Respir J 2004; 24: Suppl. 48, 557s
Year: 2004
Chemotherapy in advanced non small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005
Radiotherapy in small cell lung cancer: patient options
Source: Virtual Congress 2020 – Thoracic oncology
Year: 2020
Should there be a specific management for large cell neuroendocrine carcinoma?
Source: Annual Congress 2005 - Neuroendocrine tumours of the lung
Year: 2005
Clinicopathological prognostic factors in operated for small cell lung carcinoma or large cell neuroendocrine carcinoma patients
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
Clinical course of asymptomatic small enhancing brain nodules in patients with nonsmall cell lung cancer: do we have to follow them up?
Source: ERJ Open Res, 6 (3) 00109-2020; 10.1183/23120541.00109-2020
Year: 2020
Chemotherapy for small cell lung cancer
Source: Annual Congress 2006 - PG12 - Small cell lung cancer management
Year: 2006
Treatment of limited disease-small cell lung cancer
Source: Eur Respir Mon; 2009: 44: 299–309
Year: 2009
Pulmonary metastases from renal cell carcinoma: indications and results
Source: Eur Respir J 2002; 20: Suppl. 38, 39s
Year: 2002
Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer
Source: Eur Respir J 2006; 27: 1183-1189
Year: 2006
Lymphoepithelioma-like carcinoma of the lung in a patient withsilicosis
Source: Eur Respir J 2003; 22: 383-386
Year: 2003
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept